Co-Diagnostics acquires Idaho Molecular and Advanced Conceptions for up to 4.72M shares and warrants

Co-Diagnostics, Inc.

Total consideration: up to 4.72M shares of CODX common stock and 465,000 warrants at $9.125 exercise price.
Acquisition provides all existing and future assets and IP for at-home/point-of-care PCR device (Eikon/YourTest).
Closings expected by December 31, 2021; each target becomes wholly owned subsidiary of CODX.
Dr. Kirk Ririe to become president of subsidiary; Dr. Carl Wittwer named Chairman of Scientific Advisory Board.
CODX commits to fund development; deal streamlines commercialization and avoids future royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.